BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.61−0.07 (-0.91%)
Close on Nov 13, 2026Market cap $1.94BP/E –Yield –
BioCryst Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
BioCryst Pharmaceuticals's ebitda for the twelve months ending Dec 31, 2025 was $342.38M. For fiscal 2025 it was $342.38M. The highest annual figure on record is $342.38M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $342.38M | – |
| FY2024 | Dec 31, 2024 | -$1.30M | – |
| FY2023 | Dec 31, 2023 | -$102.05M | – |
| FY2022 | Dec 31, 2022 | -$147.00M | – |
| FY2021 | Dec 31, 2021 | -$176.94M | – |
| FY2020 | Dec 31, 2020 | -$174.01M | – |
| FY2019 | Dec 31, 2019 | -$98.73M | – |
| FY2018 | Dec 31, 2018 | -$93.45M | – |
| FY2017 | Dec 31, 2017 | -$56.71M | – |
| FY2016 | Dec 31, 2016 | -$48.12M | – |
| FY2015 | Dec 31, 2015 | -$39.26M | – |
| FY2014 | Dec 31, 2014 | -$45.59M | – |
| FY2013 | Dec 31, 2013 | -$30.41M | – |
| FY2012 | Dec 31, 2012 | -$33.26M | – |
| FY2011 | Dec 31, 2011 | -$48.70M | – |
| FY2010 | Dec 31, 2010 | -$32.09M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $260.78M | – |
| Q3 FY2025 | Sep 30, 2025 | $29.93M | +273.9% |
| Q2 FY2025 | Jun 30, 2025 | $30.12M | +231.6% |
| Q1 FY2025 | Mar 31, 2025 | $21.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.20M | – |
| Q3 FY2024 | Sep 30, 2024 | $8.00M | – |
| Q2 FY2024 | Jun 30, 2024 | $9.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.18M | – |
| Q4 FY2023 | Dec 31, 2023 | -$42.25M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.50M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.01M | – |
| Q4 FY2022 | Dec 31, 2022 | -$45.92M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.06M | – |
| Q2 FY2022 | Jun 30, 2022 | -$34.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.64M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.01M | – |
| Q3 FY2021 | Sep 30, 2021 | -$44.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$51.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$52.23M | -68817.1% |
| Q3 FY2020 | Sep 30, 2020 | -$42.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$38.33M | – |
| Q1 FY2020 | Mar 31, 2020 | -$40.76M | – |
| Q4 FY2019 | Dec 31, 2019 | $76.00K | – |
| Q3 FY2019 | Sep 30, 2019 | -$34.92M | – |
| Q2 FY2019 | Jun 30, 2019 | -$34.74M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.15M | – |
| Q4 FY2018 | Dec 31, 2018 | -$25.06M | – |
| Q3 FY2018 | Sep 30, 2018 | -$28.30M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.06M | – |
| Q1 FY2018 | Mar 31, 2018 | -$22.03M | – |
| Q4 FY2017 | Dec 31, 2017 | -$17.68M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.17M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.34M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.51M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.02M | – |
See a number that looks wrong?